Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.57 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.46 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27145372 | 0.88 | EGFR (0.57) | EGFREPHA2NSD2PIK3CADNMT3A | |
| SCHEMBL30820513 | 0.88 | EGFR (0.73) | EGFR | |
| SCHEMBL27136300 | 0.88 | EGFR (0.73) | EGFR | |
| SCHEMBL30031254 | 0.87 | EGFR (0.52) | EGFREPHA2ALKKDR | |
| SCHEMBL30820508 | 0.85 | EGFR (0.62) | EGFREPHA2 | |
| SCHEMBL27152211 | 0.85 | EGFR (0.62) | EGFREPHA2 | |
| SCHEMBL30822092 | 0.82 | EGFR (0.56) | EGFREPHA2KDR | |
| SCHEMBL27136650 | 0.82 | EGFR (0.56) | EGFREPHA2KDR | |
| SCHEMBL30032119 | 0.82 | EPHA2 (0.57) | EGFREPHA2 | |
| SCHEMBL30820474 | 0.82 | EPHA2 (0.57) | EGFREPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC. (KR) | 2024-07-25 | — | — | US | disclosed |
| CN-117693505-A | Heteroaryl derivative compounds and uses thereof | 沃若诺伊公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-4328222-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | ERBB2, EGFR, ERBB3 | EGFR 2/4885EPHA2 25/4885NSD2 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.